Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You are welcome. Best!
Promoting a product in development and prior regulatory approval is nothing wrong with it. Lots of companies have been doing just that as long as the companies states the fact that the product has yet to be approved but the companies strongly believe it will be approved based on scientific and clinical findings.
Nobody promoting their products in that way gets in jail, but somebody does get sued for misleading information if their product ultimately fails to get approved and share price tanks.
Linda Power would not want to wade into any legal implication because tons of ill-minded persons are keenly await for a legal bite. Some have already sued the company for some laughable reasons pretending they are investors of NWBO, yes probably bought a tiny position for the purpose of suing as investors.
At this critically important moment of time when the company had or has being hashing out with regulatory bodies for submissions for marketing approvals, better say nothing than anything so I fully understand the company's stance of minimal communications and absolutely no promotion.
That in and of itself has given the 7 accused MMs some field days. We investors have to face repeatedly instability of share price/movement. Some continue to accumulate, some have plenty of chance to switch moods for trading, some don't know what to do.
All are waiting for the end game: news for submitting marketing applications (based on hashed out agreement thus almost 100% guarantee for approvals), and ultimate regulatory approvals.
We are the last to laugh. For that, I accumulate.
No they are digging a hole so big and deep that they have no ways to get out. Just recently, the 7 accused MMs have to naked sell shares from as low as $0.4s to today's $0.7s. The majority of those shares sold are from MMs hands.
But I don't think they are that dumb. It's just today they can do that absent of approval news and large trading volume. Tomorrow when things change, they will be among the largest buyers to mitigate their loss.
Now it's easy to take advantage of this hardened hostility to accumulate shares if you believe we will ultimately get approval, regardless it happens this year or next.
Be happy and combative.
Without the wolfpack short and in a lesser degree Linda Powers who has to dilute shares big time for years, I would have not dared to think I can hold that a big position for a single stock for so long.
The only way to beat the shorts and in a lesser degree our Dear Linda is to average up and down until DCVax-L gets approvals.
I have taken this road no return.
Added 30k just below $0.70 on top of my existing 7-figure shares. Have powder today for more. On the back of the gorgeous MOA presented by Dr. Bosch and ever closer to approval, I don't think we are on the down trend again, today's act probably is someones who want to accumulate.
[And don't forget the truth-revealing NVCR. If only a fraction of money comes in our way, we should be in an uptrend for a long time. Remember accumulation takes time and art of execution]''
Cheer!
Folks, the review article does what a review article should do: poking holes and criticizing things of the work that have previously been done, if you know how academic world works. Yes, during this due process, there would be personal things thrusted into the supposed neutral view of the authors. In this case, the authors, even from their honest disclosure are of conflict of interests -- they themselves have been developing other kind of dc vaccines, and they have had interests from NVCR, etc. And as some posters have pointed out, their review article has not been well written and even grossly mistaken the fact of the part of DCVax JAMA paper for stating DCVax trial excludes all patients with residual tumors which is of course not true as flipper pointed out.
Well, it's generally a not out of bound review all in all. In academics, authorities (reviewing authors) always want to find faults from existing achievements to prove their "higher" existence and to pave the way for future proposals for funding so as to keeping their research new life, giving their graduate students something to do...
Its their jobs to do to find imperfection from perfection, and surprisingly it's not very difficult to do if you are familiar with the field. So if a review article on something doesn't tear it apart besides normal statement of facts, then it should not be called a review.
In my academic years, I have written several high profiles reviews. I am kind of sorry today for the folks I criticized, or should I?
Wrote a simplified this in a tweet:
$NWBO $NVCR $XBI $IBB Early $APPL $TSLA $AMZN in biotech
Investing in $NWBO & $NVCR is like investing in day & night, distinctly clear now because of #MOAs. One has a clear, understandable & brilliant #MOA applicable to all #cancers while the other not clear, incomprehensible & untalented #MOA. Recent events mark the reverse fortune of the two in a rightful way. One in early time of rising while the other fortunately backing to the ground -- why waste money & time for something finally found not working.
I said days ago on the crash of NVCR price, new blood was coming in the way of NWBO which would be sustainable. Well if the new blood is the loser NVCR institutions, then not only sustainable but powerful, but first has to be measured, then blast!
[I also said a lot of somebodies would miss out]
Yes it's not new. It's on the shelf for years collecting dust.
But, things have since changed and is about to change in a much bigger way with marketing applications or application acceptance of DCVax-L about to break on any day, and particularly with increased awareness and unprecedented rich data re MOA, substantially improved OS, etc from DCVax-L trial for GBM.
So the general dynamic has changed. With that on mind, yesterday's "garbage" such as DCVax prostate P3 trial may be today's treasure.
I will not be surprised if that specific trial gets new interests with a partnership deal.
To save you time, man up and smarten up: DI knows nothing substantially more than a keen-eye joe on the street who can access pubic information.
The company will definitely pr application submission/acceptance for various reasons -- one it's a undeniable milestone (if this is not one then there will be only one that people can call it milestone which is approvals) and two it's an golden opportunity for the management to reward themselves with out-sized options.
But it's also a forgone conclusion judged by the plenty of time having passed since data lock and trial result publication, the time between submission/acceptance and approval will be substantially shortened regardless of which route the company undertakes.
It's also a forgone conclusion the company would iron out all problems with ALL RAs concerned, not just with HMRA in UK. So when the application submission/acceptance news breaks, it's a GUARANTEE DCVax-L will be approved shortly by all RAs.
Since yesterday's reverse fortune with NVCR which finally made the investment community understand it's future is break, we are in an improved position to attract new blood, which will be substantial and sustainable.
As we are so close, many will miss out.
They should, but I have long considered SEC is like an entertaining department in Hollywood. Funny how the accused 7 MMs have been selling in the ranges of 0.5s and 0.6s against all investment principles, hoping they can buy cheaper later.
They will claim they are genuine and innocent heeding to AF's expert advice.
On today's NVCR news, there is no brainier that one should have a weighted position on NWBO!
Today's news re NVCR's lung cancer trial results is a huge wakeup call for both NVCR and NWBO investors, ans also for the general investment world:
NVCR has no future. NWBO will be the king starting today and in the future
Ignorant at best and ill wished at worst. In today's news about NVCR "positive" lung cancer trial results, It shows that "only 2% of patients in the ICI arm had prior ICI exposure while in the real world, 99% of patients get ICI treatment. A flawed trial with crooked results as usual for NVCR.
Get things straight. [so it's not sell on news but instead sell on bad news]
Anything has reason. The strange/abnormal way of nwbo communication, for example today instead of pr-ing Dr. Bosch's gorgeous presentation at ASCO, nwbo sends email to al investors who have mostly already loaded up -- obviously nwbo doesn't want to ruffle feathers of those concerned, including FDA, and those warped who would take any chance to bash and accuse the company of illegal marketing.
The very detailed, data rich presentation, for instance, full antigens uptake by DCVax vaccine from the tumors, and stimulated, multiplied and generation T-cells, B-cells seems to suggest the company may go on the route of approvals bigger and grenadier than what we have expected -- tissue/tumor agnostic -- at least exploratory for approvals for many other solid tumors.
Whatever is going on behind the scene, DCVax-L will be approved for nGBM and rGBM. We can wait for approvals for other indications later when the company has more concrete evidence to support the nature of DCVax-L as tumor agnostic.
Without the notice and interest of the general public, it may be easy for the accused MMs to contain the price, but those who know what we have, it's yet an opportunity to buy at such unbelievably low price.
Dr. Bosch's ASCO presentation appears on NWBio website: https://nwbio.com/wp-content/uploads/NWBT_ASCO_slides_06032022_FINAL.pdf
Enjoy reading.
O, yea Linda and the co. has done nothing since data lock on 5 Oct. 2020, and since stated the co. "would be strategic in filing applications in multiple places" except a no impact MIA. Very bad co., very bad investment idea, very bad management, so logically even an animal by knowing of this bad, very bad co. very bad management would have long left for much greener pastures.
Have I seen one of them leave so far? Are you guys real? With well over 7-figure shares and adding monthly, I feel I am just dumb enough wasting my time writing this dumb post, even I have not written one for days.
What the fk energy you guys have had, posting daily for years? Please share!
From WH forum on brain cancer: it's clear and loud patients need more options!
More collaboration, fucking "patients privacy" excuse.
So far it's general as expected.
Second panel: SPORE (we know UCLA Linda Liau is spearheaded in this program)
Effectiveness -- focused on survivals -- SOC is antique useless, called for advancement/breakthrough since for 2 decades there has been no change.
Exactly right LessIsMore, the earlier in the development of a company, the better chance of being invited to today's moonshot discussion; NWBO is in the process of preparations for regulatory approvals or in the process of regulatory approval, so of course NWBO should not be invited to the discussion, otherwise FDA should be disbanded.
One more example of the above argument is Kazia Therapeutics whose CEO is invited to the discussion as well, which has participated in the global GBM AGILE trial (NCT03970447) with primary completion day of June 2026, contrary to Kazia CEO's claim that its data will be available this year.
The fact is no companies whose trials are completed with positive outcomes are invited to the discussion so you better focus your efforts in reading financial filing, not anything else.
As for whether there is any hint relevant to NWBO from this afternoon's discussion, you will definitely have some as nobody can circumvent NWBO's achievement in this field: soon to be approved paradigm shift caner vaccine DCVax-L, just don't bet on direct name calling.
NWBO dangling no carrots or whipping no sticks, usually it's impatient retail investors who go ahead of themselves.
Since NWBO's DCVax-L is under the preparation by NWBO for applications for market approvals or is being reviewed by RAs, it won't be mentioned or discussed directly in tomorrow's WH moonshot youtube discussion. It's common sense.
You guys are just wasting time hoping otherwise, but there will be some categorical discussions about cancer immunotherapy including cancer vaccines.
That in and of itself may be a positive hint for what is about to happen in the horizon, and for ones who have done their own dds, a buy time.
I am not one who like to speculate anything related to nwbo from science, trial data implications to finance, but I would throw out one this time re recently received $3 million prepayment, just for fun:
simply if this is only a straightforward financing deal, or an institution which wants a big chunk of nwbo share, then a deal of this magnitude of this kind should be able to be finalized within a reasonable period of time, 16 days having passed since we knew it from 10Q, and before 10Q who know how long the parties had already discussed specific terms.
So with each additional day passes, if we still don't see a 10k filed on this regard, it becomes more apparent it's highly likely this may be a partnership deal.
The only thing seemingly against this thought is the share price which as usual having gone nowhere barring effective manipulation.
Nothing will have an impact on my position until after approvals, so just for fun.
[bty, this post is not intended to reply to FeMike, sorry]
Today's $0.5s and $0.6s are $0.1s and $0.2s years ago, the only difference is today we has JAMA Oncology paper published, MIA license and await for multiple market applications.
Not many people said they had the guts to buy when prices were in the range of $0.1s-0.2s, but tons of people have said they bought at those low price years ago. I can safely say people will say they bought at today's price, months later
LOL
Then you would have to buy at much higher price. Today added 28k more shares at slightly below $0.56, plus the last two weeks more than 100k added for my multiple accounts, not counted yet with my wife's accounts.
My holding has once again peaked, which will continue until at least first approval.
Odds of approvals has steadily climbed with more data supporting the already very positive JAMA Oncology paper conclusion, "statistically significant and clinically meaningful."
Today I still has 11K bit around $0.555. Wishing me luck and good weekend all longs.
without a shred of doubt. GL.
Sour grapes will definitely become sourer as MMs let it go as of now evidenced with thin volumes with high percentage rise of price after years long relentless manipulation. Those constant FUD spreaders hoped they could detect "any tide change" by a penny or so so they could be onboard for a penny or so swing trades would scream with more desperate FUD.
But why MMs let it go in a normal trading manner is still a mystery, but investors should have no doubt on whether this stock will be easily a ten bagger in not a distant future.
Justice will be served for the long, particularly for the patients and scientists working to conquer cancers. It is not whether but when.
Not out of woods yet, and still a window wide open for buyers.
[as of 11am, volumes accelerate which is a good sign!]
This morning I placed an order for about 30K at $0.46 just in case, and after a nap afternoon saw for a while no sellers would sell at $0.5 so I just jumped the line and placed a new order for 7K at $0.5001 (sorry for jumping the line with that tiny 0.001 difference).
Got that order filled in two batches: 5K in a few minutes, and 2k about 10 minutes later.
I have often thought recently people should be more confident to buy now at $0.50s than when the price was around $0.1s and $0.2s with data known now and odds of approval much higher and sooner.
GL
Added 7k at $0.5001, will continue until at least DCVax-L gets approved.
No words, discussion, argument or even anger at the short and manipulators but buy, buy and buy, bc everything has been said. Just patiently wait for MAA/MA/BLA and approvals.
Correction on "Go big or go home" used in my previous post: the last part of "go home" should be removed as I don't think there is much of a downside now at the price of around $0.5 with MC slightly over $500 million. I believe we will get dcvax approved by all regulatory agencies, and it's highly likely by UK this year.
I have never believed NWBO would only be worthy what its value is today so I shall say, Go Big, Bigger, and much Bigger.
[5.8k more just happened at $0.4850 [added shares today, last week, more to come]
Arh Dan
@Arhdan9
1m
$NWBO $XBI $NVCR
Lucky to add a tiny of 5.5k shares of $NWBO so far today. More to come. $NWBO market cap will pass that of $NVCR this year, going much higher there after. We all know what is going to come after super quietness [on the basis of positive data, more awareness, plenty of time to submit marketing applications to multiple RAs).
In addition to last week's purchase of 38k shares at average around $0.49 per share, hardly making a splash in repeatedly peaked 7-figure holding in terms of average share price.
Go big or go home.
Good for you to have accumulated a sizable of shares. I am in the same boat, and have dampened my expectation for a paying out day soon since we didn't see one on datalock, positive data presentation at NYAS, and JAMA Oncology publication as we had so expected if the market behaves normally.
We are in a battle with the manipulators, but my conviction is we will win at due time which I am personally afforded to well after regulatory approvals --- with revenue coming in and increasing steeply q after q. That will be my pay out day. What I can do is to continually accumulate at any possible time if the price is low.
Of course I don't rule out the manipulators would capitulate well before my tolerate day, which is very likely. It's just I have set my day well beyond, at least for my sanity so I would see any day with low price as a day of accumulation, not a day of frustration.
Good weekend to you too!
You have been here for years that you have summarize how Linda does things pretty well. So just forget about timing, instead focus on accumulating!
With NWBO, timing is the most stupid thing investors can/will do.
Anyone is prone to slip when talking too much. There is no standard for how long should it take for a company to prepare and submit an MAA or a BLA for regulatory approval, particularly considering most such applications deal wit one indication, not twos such as ours, ie, nGBM and rGBM.
It is also true this is not in the original design and it only becomes true when the trial unfolded. As a result, a well-thought out and careful preparation is warranted. I guess the company would like to supply ancillary material/data as much as possible in order to ascertain the positive outcomes. In this regard, starting "slow" may at the end expedites the approving process instead.
After all, the company has never give any specific guideline and only said it would happen this year.
My guess is we may see the news any day from now, but would not think it's out of bounds if it happens one month or so later.
Not bragging or else depending on one's perspective, I have continued adding shares which repeatedly peak for years, and will continue do so until I think it's enough at such depressed prices.
Keep the good work in the scientific ground my friend.
I have a feeling on the amended complaints due 10 April, besides spoofing, there will be violation of Rule 10b-5 under the Exchange Act for selling stock short and failing to deliver shares at the time of settlement with the purpose of driving down the security’s price. This manipulative activity, in general, would violate various securities laws. One obvious example would be trading on and shortly after 10 May 2022.
https://law.stackexchange.com/questions/70485/under-what-circumstances-are-market-makers-allowed-to-engage-in-naked-short-sel
"Rule 204 – Close-out Requirement. Rule 204 requires brokers and dealers that are participants of a registered clearing agency[8] to take action to close out failure to deliver positions. Closing out requires the broker or dealer to purchase or borrow securities of like kind and quantity. ... If a participant has a failure to deliver that the participant can demonstrate on its books and records resulted from a long sale, or that is attributable to bona fide market making activities, the participant must close out the failure to deliver by no later than the beginning of regular trading hours on the third consecutive settlement day following the settlement date, referred to as T+6. ... Rule 203(b)(3) of Regulation SHO requires that participants of a registered clearing agency must immediately purchase shares to close out failures to deliver in securities with large and persistent failures to deliver, referred to as “threshold securities,” if the failures to deliver persist for 13 consecutive settlement days
...
Selling stock short without having located stock for delivery at settlement. This activity would violate Regulation SHO, except for short sales by market makers engaged in bona fide market making. Market makers engaged in bona fide market making do not have to locate stock before selling short, because they need to be able to provide liquidity. However, market makers are not excepted from Regulation SHO’s close-out and pre-borrow requirements.
Selling stock short and failing to deliver shares at the time of settlement. Rule 204 requires firms that clear and settle trades to deliver securities to a registered clearing agency for clearance and settlement on a long or short sale in any equity security by the settlement date or to take action to close out failures to deliver by borrowing or purchasing securities of like kind and quantity ...
Selling stock short without having located stock for delivery at settlement and failing to deliver shares at the time of settlement. This activity may violate Regulation SHO’s locate and close-out requirements, as explained above. In addition, in fall 2008 the Commission adopted Rule 10b-21, referred to as the “naked” short selling antifraud rule. Those who deceive about their intention or ability to deliver securities in time for settlement are committing fraud, in violation of Rule 10b-21, when they fail to deliver securities by the settlement date.
Selling stock short and failing to deliver shares at the time of settlement with the purpose of driving down the security’s price. This manipulative activity, in general, would violate various securities laws, including Rule 10b-5 under the Exchange Act."
Saw the accused MMs have to use him/his tweet as cover for a penny or two price manipulation since his tweet.
For most pre-commercial biotech companies seeking FDA approval, manufacturing readiness is usually the last step to check by FDA before its making decision on whether to approve the underlining drug/biological product/vaccine, so in this sense June 2023 is more than achievable since UK MHRA has just checked the readiness item (module).
By the time when MAA is submitted, it's also possible MHRA has reviewed most, if not all contents of MAA, so it is certainly possible the approval may come earlier than a lot of folks would expect.
Regardless, it becomes easier by the days/months to hold and/or add more shares as we have done just that already for years, if not a decade.
Your frustration is warranted, but the window of frustration is quickly shrinking. I am a buyer, to be exact, have been a buyer with price in this depressed range, having averaged up with buys as high as $1.6s, and as low as low $0.4s with huge numbers on 10 May, as recently as yesterday at $0.57 and up.
I know I am going to be happier with each buy as day passes by.
As least the time to approval is quickly shrinking.
Was Dr. Bosch supposed to present not only P3 trial data, which is gorgeous with some added tidbits, but also MANUFACTURING? Where is MANUFACTURING part in the powerpoint?
MIA + imminent.
As said before, bought 18K shares at price ranging from $0.57-0.585. Loved this price as MMs have resorted to scare tactics baring no news.
Nobody knows when news comes.
After chasing bits up this morning, first set at $0.56, and then all the way up to $0.585, never got filled below $0.57 though, would take a break this morning.
Will be back this afternoon.
JAMA Oncology paper, increasingly bullish GBM sphere, increased retail investor base, cornered regulatory agencies failing to act fast and proactive, accused MMs on watch, expending patents and manufacturing, now we just need a trigger.
Under the current market circumstances, NWBO's loan with John Fife is reasonably good financing deal we can expect for. No dilution, reasonable cost with annualized rate around 17%.
Better than issuing enough C-shares at distressed price.
Better than toxic diluted financing, issuing shares and/or warrant.
Yes, there are always some people who don't like it.
As retail, I had chased the bits up, and still not got filled for my last bit for 3600 shares at $0.60 routed to CEDL on Friday.
Going to buy more coming Monday.
Annual interest rate for NWBO's $11 million loan with John Fife:
Quoted a poster who said, "I did this for a living for way too long."
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171420045
His post I quote (within quotation marks):
"LOL wow Kab is that how you calculate interest? Just add them up?
From my post yesterday.
Distressed financing once again:
8% interest on loan
10% OID
10% "premium" added to 14 monthly installments
I've calculated a 25.2% effective annual rate on this loan."
Source post: https://investorshub.advfn.com/boards/replies.aspx?msg=171412867
Today in reply to this post: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171422379 which shows detailed month by month calculations indicating annual interest rate is about 17%, he says (I quote, within quotation marks):
" The only correction that I see is that the amount received = $9,904,500. If there's wordage in the loan that says $10M received please let me know.
I made an error in that I calculated the term at 21 months instead of 22. We are almost identical in total amount paid.
I also used compound interest in my calcuations.
Nice work!"
(source post: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171423758)
As of now, the post who makes living by doing this kind of things seems still to get it wrong with the amount received. The poster still believes it is $9,904,500 instead of $10M. LOL
Conclusion: aperture007 in his post has demonstrated with detailed month by month calculations how this loan will be charged and paid, and the annual interest rate is about 17%, not 25% or 39%.
The question is if any ones who want to invest in NWBO, particularly those who make living by doing this kind of things, how can they get such calculations awfully wrong? And why have they as experts got such thing, and to be accurate pretty much anything nwbo persistently wrong?
[another expert say the rate is 30%: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171422511]
bought a bunch again, even chased up bits. My last bit for 3600 at $0.60 (routed to cdel) have not got filled before market close.
cheer!